Access Bio Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Young-Ho Choi
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
Access Bio, Inc.'s (KOSDAQ:950130) Prospects Need A Boost To Lift Shares
Nov 13
Optimistic Investors Push Access Bio, Inc. (KOSDAQ:950130) Shares Up 38% But Growth Is Lacking
Aug 07Access Bio's (KOSDAQ:950130) Earnings Are Weaker Than They Seem
Mar 26Is Access Bio (KOSDAQ:950130) A Risky Investment?
Mar 25If You Had Bought Access Bio (KOSDAQ:950130) Shares A Year Ago You'd Have Earned 740% Returns
Feb 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -₩13b |
| Jun 30 2024 | n/a | n/a | -₩16b |
| Mar 31 2024 | n/a | n/a | -₩42b |
| Dec 31 2023 | n/a | n/a | -₩3b |
| Sep 30 2023 | n/a | n/a | ₩7b |
| Jun 30 2023 | n/a | n/a | -₩2b |
| Mar 31 2023 | n/a | n/a | ₩100b |
| Dec 31 2022 | n/a | n/a | ₩347b |
| Sep 30 2022 | n/a | n/a | ₩418b |
| Jun 30 2022 | n/a | n/a | ₩453b |
| Mar 31 2022 | n/a | n/a | ₩356b |
| Dec 31 2021 | n/a | n/a | ₩190b |
| Sep 30 2021 | n/a | n/a | ₩168b |
| Jun 30 2021 | n/a | n/a | ₩151b |
| Mar 31 2021 | n/a | n/a | ₩172b |
| Dec 31 2020 | ₩1b | ₩326m | ₩48b |
Compensation vs Market: Insufficient data to establish whether Young-Ho's total compensation is reasonable compared to companies of similar size in the KR market.
Compensation vs Earnings: Insufficient data to compare Young-Ho's compensation with company performance.
CEO
Young-Ho Choi (60 yo)
no data
Tenure
₩1,253,201,612
Compensation
Mr. Young-Ho Choi serves as Chief Executive Officer and President of Access Bio, Inc. Mr. Choi has R&D and managements experience for IVD field. Mr. Choi is an Oak Ridge Conference Outstanding Awardee for...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 02:07 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Access Bio, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jongsun Park | Eugene Investment & Securities Co Ltd. |
| Gwang Sik Park | Kyobo Securities Co., Ltd |
| Kyung-Churl Noh | SK Securities Co., Ltd. |